Immunogenic Cell Death and immunomodulation by Cancer therapy: Role of Chemoimmunotherapy in the Clinic
Although cancer chemotherapy has historically been considered immune suppressive, we now understand that combining chemoimmunotherapy incites a mechanism called Immunogenic cell death. These mechanisms are now moving from concepts to the clinic. Recently dramatic advances in lung cancer treatment by combining chemotherapy with immunotherapy have led the way to this new frontier in cancer medicine. We will explain the mechanism behind ICD and how it will perhaps breathe a new life into chemotherapy use in cancer, not front and center but as a helpful hand to immunotherapy.
We now believe that how cells die during chemotherapy is critical 1; Although cancer chemotherapy has historically been considered immune suppressive and has been assumed to be detrimental to any potential immune response2. Certain chemotherapies can augment tumor immunity by ‘Immunogenic cell death’ (ICD), and apoptosis is not A non immunogenic event as it has been thought to be1,3. Inciting ICD is dependent on the drug its dose, and the schedule of chemotherapy administration[STROKUS]5. However, certain types of apoptotic cell death can lead to activation of the adaptive arm of the immune system and disrupt strategies that tumors use for evasion of immune surveillance1,5
Non-immunogenic vs Immunogenic Cell death
Non-immunogenic cell death involves cell membrane breakdown and release of phosphatidylserine (PS) which are non immunogenic parts of a cell membrane which gets engulfed by macrophages leading to sequestration of any tumor antigens from immune surveillance6. PS down plays this process further by by upregulating TGF β (Transforming growth factor-β) and Interleukin-10 thereby making the death of the tumor cell a non immunogenic event thereby bypassing the adaptive arm of the immune system7.
Some instances of cell apoptosis induced by chemotherapy and or radiation appear to be more efficient at illiciting the adaptive immune system rather than tumor cell undergoing necrosis or osmotic lysis, suggesting that clearance of apoptotic and necrotic cells in vivo is rather different9,10.
The ability of cancer cells to elicit an immune response is perhaps dictated by CDAMs (cell death-associated molecules) emitted a dying tumor cells1,9,10,12. CDAMs that are exposed on the surface of tumor cells or released include calreticulin (CRT), ATP, high mobility group box 1 (HMGB1) etc. These help in exerting a potent immunostimulatory effect10.
Conventional chemotherapeutics although may be immunosuppressive may also potentiate for enhanced immunotherapeutic outcome during the immune reconstitution phase following chemotherapy induced lymphopenia10,13. One mechanism is through stimulation of MHC class I expression and expressing tumor antigen expression referred to as ‘epitope spreading’. The altered MHC class I peptides expression, expression of altered normal proteins, defective ribosomal products (DRiPs) peptides generated by prematurely terminated and misfolded peptides etc. tags the cancer cells to be recognized by T cells for cell death10,14.
There also seems to be distinct antineoplastic agents at narrow dosing range that improve the immunogenicity of tumors as they stimulate them to emit various immunostimulatory signals called DAMP (Damage associated molecular signals)1,15. Typically, ER Stress response in tumor cells leads to CRT exposure which signals to dendritic cells to engulf the tumor10. Premortem autophagy leads to ATP secretion and extracellular ATP acts on so-called purinergic receptors including metabotropic P2RY2 and ionotropic P2RX7 receptors cajoling DC precursors and neutrophils into the tumor bed expressing CD11c(+)CD11b(+)Ly6C(hi) engulfing tumor antigens in situ and presented them to T lymphocytes in an anthracycline exposed murine models16. Secondary necrosis leads to HMGB1 17, annexin A1 (ANXA1) release binding to TLR4 (Toll-like receptors) on mature dendritic cells that process the antigen this can be subverted by TLR4 SNP or HMGB1 loss1,18. DNA damaging agents has been shown to stimulate the expression of death receptors. FAS (also known as CD95) and TNF-related apoptosis-inducing ligand (TRAIL) receptors 1,2 on tumor cell surface19 and in the presence of their respective ligands (FASL)/ TRAIL, produced by immune effector cells20 can induce immunogenic cell death21.
Through multiple cytokines and chemokines, including CXCL1, CCL2, IL-6, and IL-8 these tumors become susceptible to the cytotoxic activity of several innate and adaptive immune effectors like NK cells22 further increasing CRT exposure23.
Despite the excitement surrounding checkpoint inhibitors, most patients do not respond to immunotherapy. There is, however, growing interest in combining these agents with chemotherapy, radiotherapy, and other treatments to boost their efficacy24.
We are now able to somewhat understand as to how to activate Antigen-presenting cells, and T cells in patients with advanced disease, whose immune systems have weakened25. Intact immunogenicity is required in, a large part, to effectively prime antitumor CD8+ T cells8. In this respect, the process of tumor cell death will determine whether the initial interaction between the DC and the tumor cell yields an event of immunologic significance or not4.
Necrosis induced by therapy is a source of antigenic substrate for Dendritic cells to present to T cells4,10,25. Obeid et al. suggested that some chemotherapy agents can induce more immunogenic cell death than others25.
Many anticancer agents used at their maximum tolerated dose can exert myelosuppressive and immunosuppressive effects[finn,2012]. Anticancer agents used at clinically useful doses (usually below the maximum tolerated dose) may mediate rapid immunostimulatory effects10.
For instance, the vaccination of cancer patients receiving standard-of-care chemotherapy can result in vigorous immune responses challenging the notion that chemotherapeutics only causes immunosuppression10. Ipilimumab can effectively be combined with antineoplastic agents such as fotemustine and temozolomide (for the treatment of metastatic melanoma) or paclitaxel plus carboplatin (in individuals bearing non-small-cell lung carcinoma)26,27. Combination treatments of chemoimmunotherapy would not have been effective if chemotherapy only led to severe immunosuppression10,15,25
Recent Clinical Data
We have made incredible progress in bringing the concept of ICD from a concept to clinic. The recent AACR and ASCO presentation of chemoimmunotherapy trials and their success have led the way to possible change of the standard of care (Table 1).
Among the initial clinical data was the cohort C of KEYNOTE-021, the dose-finding cohort for the combination of pembrolizumab plus carboplatin and pemetrexed, there was no apparent relationship between PD-L1 expression and response, with more than 60% of patients achieving a response across the PD-L1 tumor proportion score subgroups with PFS >10 months28.
KEYNOTE-021 showed the addition of pembrolizumab to standard-of-care chemotherapy followed by pembrolizumab for 2 years and pemetrexed maintenance therapy significantly improved objective response (55%) compared with chemotherapy alone in chemotherapy naïve patients with NSCLC[LANGER, 2016]. This combination significantly prolonged progression-free survival (PFS) in this non-squamous NSCLC population to 13·0 months for pembrolizumab plus chemotherapy compared to 8·9 months for chemotherapy alone.
This concept is being studied in the KEYNOTE-189 study and the KEYNOTE-407 study of carboplatin and paclitaxel or nab-paclitaxel with or without pembrolizumab for squamous histology (ClinicalTrials.gov, number NCT02775435)29. In May 2017 FDA approved pembrolizumab plus pemetrexed and carboplatin-based chemotherapy as first-line treatment for patients with advanced nonsquamous NSCLC based on the phase II cohort G of the KEYNOTE-021 study.
Keynote 189 was the natural phase III extension of the earlier studies in first-line metastatic nonsquamous NSCLC patients. Patients were randomized in a 2:1 fashion, to receive platinum and pemetrexed-based chemotherapy with either pembrolizumab (test arm) or placebo (control arm).
After a 10.5-month median follow-up; median OS was not reached in the pembrolizumab arm, versus 11.3 months in the control arm. The pembrolizumab test arm was 51 percent less likely to die, compared with 58% reduction in the high PD-L1 group. However, a clear survival benefit was seen across all groups despite a 50 percent crossover rate 30.
Similarly, the IMpower150 trial met its co-primary PFS and OS endpoints, across all PD-L1 subgroups in first-line treatment of nonsquamous NSCLC with the combination of atezolizumab and bevacizumab plus a platinum doublet. The median OS with the presence of atezolizumab was 19.2 months compared with 14.7 months in the non-PD-L1 inhibitor group of Bevacizumab, carboplatin and platinum (HR, 0.78)31.
The ImPOWER 131, a phase III study of squamous NSCLC recently presented at ASCO 2018 showed a doubling of PFS. Twenty nine percent of all patients, regardless of PD-L1 expression, had a reduced risk of disease worsening or death regardless of PD-L1 expression, had a reduced risk of disease worsening or death, compared with those who received chemotherapy alone 32. The Checkmate 227 is looking at activity in combination of immunotherapies. Recently published data showed a significant longer progression-free survival with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. Median PFS was 7.2 months in the nivolumab/ipilimumab arm vs 5.5 months in the chemotherapy arm (HR = 0.58)33.
Recent exciting changes in front lie treatment of lung cancer combining chemotherapy and immunotherapy have brought the concept of immunogenic cell death to the clinic and promises to usher a new realm in the treatment of metastatic lung cancer. The role of chemotherapy may not be front and center but is definitely not over as of yet.
|NCT Number||Title||Recruitment||Phases||Start Date||Completion Date|
|NCT02775435||A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)||Recruiting||Phase 3||Jun-16||Aug-19|
|NCT02591615||Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC||Recruiting||Phase 2||Mar-16||Dec-19|
|NCT02564380||Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous – Non-Small Cell Lung Cancer (sNSCLC)||Recruiting||Phase 2||Mar-16||Sep-19|
|NCT03242915||Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)||Not yet recruiting||Phase 2||Aug-17||Aug-22|
|NCT02578680||Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)||Active, not recruiting||Phase 3||Jan-16||26-Apr-19|
|NCT02039674||A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-/KEYNOTE-021)||Active, not recruiting||Phase 1|Phase 2||Feb-14||Oct-19|
|NCT02621398||Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer||Recruiting||Phase 1||Apr-16||Sep-19|
|NCT01840579||Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)||Recruiting||Phase 1||Apr-13||15-Dec-19|
|NCT03134456||Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX||Not yet recruiting||Phase 4||Aug-17||29-Feb-20|
|NCT02987998||Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC||Recruiting||Phase 1||May-17||Jan-20|
1. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nature Reviews Immunology. 2016;17:97-111.
2. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004;4(8):592-603.
3. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482-491.
4. Storkus WJ, Falo LD, Jr. A ‘good death’ for tumor immunology. Nat Med. 2007;13(1):28-30.
5. Emens LA, Middleton G. The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies. Cancer Immunol Res. 2015;3(5):436-443.
6. van der Most RG, Robinson BW, Lake RA. Combining immunotherapy with chemotherapy to treat cancer. Discov Med. 2005;5(27):265-270.
7. Yatim N, Cullen S, Albert ML. Dying cells actively regulate adaptive immune responses. Nat Rev Immunol. 2017;17(4):262-275.
8. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-224.
9. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
10. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39(1):74-88.
11. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339(6117):286-291.
12. Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3(9):e955691.
13. Sanchez-Perez L, Suryadevara CM, Choi BD, Reap EA, Sampson JH. Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Oncoimmunology. 2014;3(7).
14. Yewdell JW. DRiPs Solidify: Progress in Understanding Endogenous MHC Class I Antigen Processing. Trends Immunol. 2011;32(11):548-558.
15. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715-727.
16. Ma Y, Adjemian S, Mattarollo SR, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729-741.
17. Bianchi ME. HMGB1 loves company. J Leukoc Biol. 2009;86(3):573-576.
18. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47-59.
19. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700-714.
20. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther. 2012;11(1):3-13.
21. Panaretakis T, Kepp O, Brockmeier U, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28(5):578-590.
22. Chan CJ, Andrews DM, McLaughlin NM, et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol. 2010;184(2):902-911.
23. Sukkurwala AQ, Martins I, Wang Y, et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. In: Cell Death Differ. Vol 21.2014:59-68.
24. Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125(9):3377-3383.
25. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54-61.
26. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046-2054.
27. Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol. 2013;25(2):166-172.
28. Gadgeel SM, Stevenson J, Langer CJ, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. http://dxdoiorg/101200/JCO20163415_suppl9016. 2017.
29. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497-1508.
30. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078-2092.
31. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301.
32. Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. Journal of Clinical Oncology. 2018;36(18_suppl):LBA9000-LBA9000.
33. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093-2104.
34. Liu SV, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2015;33(15_suppl):8030-8030.
35. Giaccone G, Camidge DR, Liu SV, et al. 513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study. European Journal of Cancer. 2015;51:S107-S108.
Cite This Work
To export a reference to this article please select a referencing stye below:
Related ServicesView all
DMCA / Removal Request
If you are the original writer of this dissertation and no longer wish to have your work published on the UKDiss.com website then please: